pH responsive delivery of lumefantrine with calcium phosphate nanoparticles loaded lipidic cubosomes for the site specific treatment of lung cancer

Sethuraman, Vaidevi; Janakiraman, Kumar; Krishnaswami, Venkateshwaran; Natesan, Subramanian; Kandasamy, Ruckmani

doi:10.1016/j.chemphyslip.2019.03.016

Cited by 31 publications

(11 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cytotoxicity effect and drug release data proves the localization of the nanocarrier in A549 lung cancer cell lines. 257 CaP-NP hybrid nanocarriers have also been found beneficial in prostate cancer therapy. In terms of capturing pH and glutathione responsiveness simultaneously, another group designed a pH and glutathione-responsive CaP-NP carrier to codeliver zoledronate and docetaxel to treat bone metastasis of prostate cancer.…”

Section: Inorganic Nddss In Cancer Therapymentioning

confidence: 99%

Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review

Khan

Hossain

et al. 2022

ACS Appl. Bio Mater.

209

View full text Add to dashboard Cite

Traditional treatment approaches for cancer involve intravenous chemotherapy or other forms of drug delivery. These therapeutic measures suffer from several limitations such as nonspecific targeting, poor biodistribution, and buildup of drug resistances. However, significant technological advancements have been made in terms of superior modes of drug delivery over the last few decades. Technical capability in analyzing the molecular mechanisms of tumor biology, nanotechnologyparticularly the development of biocompatible nanoparticles, surface modification techniques, microelectronics, and material scienceshas increased. As a result, a significant number of nanostructured carriers that can deliver drugs to specific cancerous sites with high efficiency have been developed. This particular maneuver that enables the introduction of a therapeutic nanostructured substance in the body by controlling the rate, time, and place is defined as the nanostructured drug delivery system (NDDS). Because of their versatility and ability to incorporate features such as specific targeting, water solubility, stability, biocompatibility, degradability, and ability to reverse drug resistance, they have attracted the interest of the scientific community, in general, and nanotechnologists as well as biomedical scientists. To keep pace with the rapid advancement of nanotechnology, specific technical aspects of the recent NDDSs and their prospects need to be reported coherently. To address these ongoing issues, this review article provides an overview of different NDDSs such as lipids, polymers, and inorganic nanoparticles. In addition, this review also reports the challenges of current NDDSs and points out the prospective research directions of these nanocarriers. From our focused review, we conclude that still now the most advanced and potent field of application for NDDSs is lipid-based, while other significantly potential fields include polymer-based and inorganic NDDSs. However, despite the promises, challenges remain in practical implementations of such NDDSs in terms of dosage and stability, and caution should be exercised regarding biocompatibility of materials. Considering these aspects objectively, this review on NDDSs will be particularly of interest for small-to-large scale industrial researchers and academicians with expertise in drug delivery, cancer research, and nanotechnology.

show abstract

Section: Inorganic Nddss In Cancer Therapymentioning

confidence: 99%

Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review

Khan

Hossain

et al. 2022

ACS Appl. Bio Mater.

209

View full text Add to dashboard Cite

show abstract

“…In A549 cells, the cubosomes formulation demonstrated significantly greater anticancer and anti-angiogenesis action than the medication alone. [104] 13…”

Section: Anticancer Activity Of Cubosomementioning

confidence: 99%

“…The cubosomes had shown encapsulating capacity of 78 % and a particle size of 259 nm. In A549 cells, the cubosomes formulation demonstrated significantly greater anticancer and anti-angiogenesis action than the medication alone [ 104 ].…”

Section: Anticancer Activity Of Cubosomementioning

confidence: 99%

Development, Therapeutic Evaluation and Theranostic Applications of Cubosomes on Cancers: An Updated Review

Almoshari

2022

Pharmaceutics

View full text Add to dashboard Cite

Cancer is a group of disorders characterized by aberrant gene function and alterations in gene expression patterns. In 2020, it was anticipated that 19 million new cancer cases would be diagnosed globally, with around 10 million cancer deaths. Late diagnosis and interventions are the leading causes of cancer-related mortality. In addition, the absence of comprehensive cancer therapy adds to the burden. Many lyotropic non-lamellar liquid-crystalline-nanoparticle-mediated formulations have been developed in the last few decades, with promising results in drug delivery, therapeutics, and diagnostics. Cubosomes are nano-structured liquid-crystalline particles made of specific amphiphilic lipids in particular proportions. Their ability to encapsulate lipophilic, hydrophilic, and amphiphilic molecules within their structure makes them one of a kind. They are biocompatible, versatile drug carriers that can deliver medications through various routes of administration. Many preclinical studies on the use of cubosomes in cancer treatment and theranostic applications have been conducted. However, before cubosomes may be employed in clinical practice, significant technical advances must be accomplished. This review summarizes the development of cubosomes and their multifunctional role in cancer treatment based on the most recent reports.

show abstract

“…Whereas cubosomes were previously sterically stabilized by PEGylated lipids and non-ionic copolymer shells [93,94], more recent research directions tend to combine the advantages of both lipid and polymer derivatives [95][96][97][98][99][100][101][102]. Furthermore, the production of composite cubosomes and cubic phases by associating lipids with macromolecules of pH-dependent structure, including large proteins, polypeptides, polymers, polysaccharides and peptide conjugates [21,97,103,104], can provide a wider range of novel delivery systems [105][106][107][108][109][110][111][112].…”

Section: Perspectives Of Ph-sensitive Cubosomesmentioning

confidence: 99%

Advances in the Design of pH-Sensitive Cubosome Liquid Crystalline Nanocarriers for Drug Delivery Applications

2020

View full text Add to dashboard Cite

Nanostructure bicontinuous cubic phase self-assembled materials are receiving expanding applications as biocompatible delivery systems in various therapeutic fields. The functionalization of cubosome, spongosome, hexosome and liposome nanocarriers by pH-sensitive lipids and/or pH-sensitive polymer shells offers new opportunities for oral and topical drug delivery towards a new generation of cancer therapies. The electrochemical behavior of drug compounds may favor pH-triggered drug release as well. Here, we highlight recent investigations, which explore the phase behavior of mixed nonlamellar lipid/fatty acid or phospholipid systems for the design of pH-responsive and mucoadhesive drug delivery systems with sustained-release properties. X-ray diffraction and small-angle X-ray scattering (SAXS) techniques are widely used in the development of innovative delivery assemblies through detailed structural analyses of multiple amphiphilic compositions from the lipid/co-lipid/water phase diagrams. pH-responsive nanoscale materials and nanoparticles are required for challenging therapeutic applications such as oral delivery of therapeutic proteins and peptides as well as of poorly water-soluble substances. Perspective nanomedicine developments with smart cubosome nanocarriers may exploit compositions elaborated to overcome the intestinal obstacles, dual-drug loaded pH-sensitive liquid crystalline architectures aiming at enhanced therapeutic efficacy, as well as composite (lipid/polyelectrolyte) types of mucoadhesive controlled release colloidal cubosomal formulations for the improvement of the drugs’ bioavailability.

show abstract

pH responsive delivery of lumefantrine with calcium phosphate nanoparticles loaded lipidic cubosomes for the site specific treatment of lung cancer

Cited by 31 publications

References 60 publications

Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review

Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review

Development, Therapeutic Evaluation and Theranostic Applications of Cubosomes on Cancers: An Updated Review

Advances in the Design of pH-Sensitive Cubosome Liquid Crystalline Nanocarriers for Drug Delivery Applications

Contact Info

Product

Resources

About